Comparison of neuromuscular blockade and recovery with botulinum toxins A and F
- PMID: 12210370
- DOI: 10.1002/mus.10213
Comparison of neuromuscular blockade and recovery with botulinum toxins A and F
Abstract
Intramuscular injection of botulinum toxin A is used to treat focal dystonias. Because immunoresistance has been documented in some patients, other molecular forms of the toxin have been evaluated clinically. The present investigation compared the time course and extent of neuromuscular blockade and recovery of botulinum toxin types A and F using an electromyographic monitoring system implanted in the rat hindlimb. For a given dose, the degree and duration of blockade was more complete with type A toxin. Delayed onset of recovery in animals that received high doses of type A toxin allowed time for denervative changes to prevent a full return to baseline, as confirmed histologically. Conversely, animals receiving type F toxin fully recovered within 30 days at all dose levels. The rapid recovery with type F toxin suggested that neuromuscular transmission was restored via the original terminals rather than through functional collateral sprouting. The reversible nature of blockade with this molecular species puts in question its future clinical utility.
Copyright 2002 Wiley Periodicals, Inc.
Similar articles
-
Increased efficacy and decreased systemic-effects of botulinum toxin A injection after active or passive muscle manipulation.Dev Med Child Neurol. 2007 Dec;49(12):907-14. doi: 10.1111/j.1469-8749.2007.00907.x. Dev Med Child Neurol. 2007. PMID: 18039237
-
Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy.Headache. 2004 Jan;44(1):35-42; discussion 42-3. doi: 10.1111/j.1526-4610.2004.04007.x. Headache. 2004. PMID: 14979881
-
Effects of botulinum toxin A on functional outcome during distraction osteogenesis.J Orthop Res. 2007 May;25(5):656-64. doi: 10.1002/jor.20349. J Orthop Res. 2007. PMID: 17262822
-
[Advances in botulinum toxin applications].Pol Merkur Lekarski. 1999 Sep;7(39):134-7. Pol Merkur Lekarski. 1999. PMID: 10598494 Review. Polish.
-
[Botulinum toxin type A and cholinergic system].Lijec Vjesn. 2007 Dec;129(12):407-14. Lijec Vjesn. 2007. PMID: 18383744 Review. Croatian.
Cited by
-
The Expanding Therapeutic Utility of Botulinum Neurotoxins.Toxins (Basel). 2018 May 18;10(5):208. doi: 10.3390/toxins10050208. Toxins (Basel). 2018. PMID: 29783676 Free PMC article. Review.
-
Skeletal muscle fibrosis and stiffness increase after rotator cuff tendon injury and neuromuscular compromise in a rat model.J Orthop Res. 2014 Sep;32(9):1111-6. doi: 10.1002/jor.22646. Epub 2014 May 19. J Orthop Res. 2014. PMID: 24838823 Free PMC article.
-
Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F.Neurotox Res. 2006 Apr;9(2-3):127-31. doi: 10.1007/BF03033930. Neurotox Res. 2006. PMID: 16785109 Clinical Trial.
-
Long-Term Effects of Botulinum Toxin Complex Type A Injection on Mechano- and Metabo-Sensitive Afferent Fibers Originating from Gastrocnemius Muscle.PLoS One. 2015 Oct 20;10(10):e0140439. doi: 10.1371/journal.pone.0140439. eCollection 2015. PLoS One. 2015. PMID: 26485650 Free PMC article.
-
The blockade of the neurotransmitter release apparatus by botulinum neurotoxins.Cell Mol Life Sci. 2014 Mar;71(5):793-811. doi: 10.1007/s00018-013-1380-7. Epub 2013 Jun 11. Cell Mol Life Sci. 2014. PMID: 23749048 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical